RS62558B1 - Frakcije krvne plazme kao terapija za kognitivne poremećaje povezane sa starenjem - Google Patents
Frakcije krvne plazme kao terapija za kognitivne poremećaje povezane sa starenjemInfo
- Publication number
- RS62558B1 RS62558B1 RS20211337A RSP20211337A RS62558B1 RS 62558 B1 RS62558 B1 RS 62558B1 RS 20211337 A RS20211337 A RS 20211337A RS P20211337 A RSP20211337 A RS P20211337A RS 62558 B1 RS62558 B1 RS 62558B1
- Authority
- RS
- Serbia
- Prior art keywords
- aging
- treatment
- blood plasma
- cognitive disorders
- plasma fractions
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title 1
- 230000002431 foraging effect Effects 0.000 title 1
- 210000002381 plasma Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662376529P | 2016-08-18 | 2016-08-18 | |
US201662412258P | 2016-10-24 | 2016-10-24 | |
PCT/US2017/029953 WO2018034712A1 (en) | 2016-08-18 | 2017-04-27 | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
EP17841780.4A EP3484502B1 (en) | 2016-08-18 | 2017-04-27 | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
RS62558B1 true RS62558B1 (sr) | 2021-12-31 |
Family
ID=61196950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20211337A RS62558B1 (sr) | 2016-08-18 | 2017-04-27 | Frakcije krvne plazme kao terapija za kognitivne poremećaje povezane sa starenjem |
Country Status (28)
Country | Link |
---|---|
US (2) | US20190321449A1 (sr) |
EP (2) | EP3995140A1 (sr) |
JP (3) | JP7316931B2 (sr) |
KR (3) | KR20220107322A (sr) |
CN (2) | CN109963582B (sr) |
AU (3) | AU2017312722B2 (sr) |
BR (1) | BR112019003172A2 (sr) |
CA (1) | CA3033051A1 (sr) |
CL (1) | CL2019000304A1 (sr) |
CY (1) | CY1124695T1 (sr) |
DK (1) | DK3484502T3 (sr) |
ES (1) | ES2899147T3 (sr) |
HR (1) | HRP20211628T1 (sr) |
HU (1) | HUE056294T2 (sr) |
IL (2) | IL264660B2 (sr) |
LT (1) | LT3484502T (sr) |
MA (1) | MA45692B1 (sr) |
MD (1) | MD3484502T2 (sr) |
MX (1) | MX2019001718A (sr) |
NZ (1) | NZ750885A (sr) |
PL (1) | PL3484502T3 (sr) |
PT (1) | PT3484502T (sr) |
RS (1) | RS62558B1 (sr) |
SG (1) | SG11201901273TA (sr) |
SI (1) | SI3484502T1 (sr) |
UA (1) | UA126232C2 (sr) |
WO (1) | WO2018034712A1 (sr) |
ZA (1) | ZA202004834B (sr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4299129A3 (en) * | 2017-04-26 | 2024-03-20 | Alkahest, Inc. | Dosing regimen for treatment of cognitive impairments with blood plasma products |
BR112020023001A2 (pt) | 2018-05-15 | 2021-02-02 | Alkahest, Inc. | tratamento de doença associada ao envelhecimento com moduladores da leucotrieno a4 hidrolase |
CN110724176B (zh) * | 2018-07-16 | 2021-10-26 | 北京豪思生物科技有限公司 | 一种治疗阿尔茨海默症的血浆蛋白分离物及其制备方法和应用 |
CN110787187B (zh) * | 2018-07-16 | 2022-05-13 | 北京豪思生物科技股份有限公司 | 一种增强记忆力和提高认知功能的血浆混合物及其制备方法和应用 |
WO2020018343A1 (en) * | 2018-07-20 | 2020-01-23 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
AU2019364271A1 (en) | 2018-10-26 | 2021-06-03 | Alkahest, Inc. | Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery |
CN110448686B (zh) * | 2019-09-19 | 2022-11-04 | 北京豪思生物科技股份有限公司 | 铜蓝蛋白联合运铁蛋白的应用 |
US20220362293A1 (en) * | 2019-09-25 | 2022-11-17 | Cytegen Corp. | Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products |
JP2022553837A (ja) | 2019-11-04 | 2022-12-26 | アルカヘスト,インコーポレイテッド | 筋肉再生に使用するための血漿画分 |
US11484551B2 (en) | 2019-11-20 | 2022-11-01 | Alkahest, Inc. | Method of treating liver failure with plasma fraction IV-4 |
AU2020388572A1 (en) | 2019-11-20 | 2022-05-26 | Alkahest, Inc. | Blood plasma fractions for use in liver regeneration |
WO2023076679A1 (en) | 2021-11-01 | 2023-05-04 | Alkahest, Inc. | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3869431A (en) | 1973-03-12 | 1975-03-04 | Firestone Tire & Rubber Co | Polyamides and their production |
US4624780A (en) | 1982-06-28 | 1986-11-25 | Alpha Therapeutic Corporation | Fractionation of blood plasma |
DE3612137A1 (de) * | 1986-04-10 | 1987-10-15 | Biotest Pharma Gmbh | Steriles plasmaaustauschmittel |
US5138034A (en) * | 1989-07-12 | 1992-08-11 | The Green Cross Corporation | Method of fractionating plasma proteins |
US5110907A (en) | 1989-08-01 | 1992-05-05 | Alpha Therapeutic Corporation | Factor viii complex purification using heparin affinity chromatography |
US5288853A (en) | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
US5219995A (en) | 1992-07-14 | 1993-06-15 | Alpha Therapeutic Corporation | Plasma fraction purification |
US5561115A (en) * | 1994-08-10 | 1996-10-01 | Bayer Corporation | Low temperature albumin fractionation using sodium caprylate as a partitioning agent |
US20050143310A1 (en) * | 2001-05-11 | 2005-06-30 | Masaki Hirashima | Novel remedies for neurodegenerative disease |
AU2003303198A1 (en) * | 2002-12-19 | 2004-07-14 | New York University | Method for treating amyloid disease |
US20040146565A1 (en) * | 2003-01-28 | 2004-07-29 | Lauridsen Group Incorporated | First lipoprotein fraction and therapeutic compositions of same |
US20130121979A1 (en) * | 2003-12-29 | 2013-05-16 | Allan Mishra | Method of treating cancer using platelet compositions |
ES2257225B1 (es) | 2006-02-17 | 2007-03-16 | Grifols, S.A | Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion. |
ES2332846B1 (es) * | 2007-10-26 | 2010-07-08 | Grifols, S.A. | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. |
PT2271382E (pt) | 2008-04-15 | 2013-05-07 | Grifols Therapeutics Inc | Ultrafiltração em dois andares/diafiltração |
US20090297485A1 (en) * | 2008-05-28 | 2009-12-03 | Allan Mishra | Compositions and methods for treating psychiatric and neurodegenerative disorders |
AU2013203043B2 (en) * | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
PT2994160T (pt) * | 2013-05-06 | 2019-08-07 | Baxalta Inc | Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada |
MX2016007492A (es) * | 2013-12-09 | 2017-03-06 | Univ Leland Stanford Junior | Métodos y composiciones para el tratamiento de afecciones asociadas con el envejecimiento. |
ES2524516B1 (es) | 2014-05-29 | 2015-03-31 | Grifols Worldwide Operations Limited | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
EA039316B1 (ru) * | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
US11040068B2 (en) * | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
EP4299129A3 (en) * | 2017-04-26 | 2024-03-20 | Alkahest, Inc. | Dosing regimen for treatment of cognitive impairments with blood plasma products |
-
2017
- 2017-04-27 UA UAA201901438A patent/UA126232C2/uk unknown
- 2017-04-27 SI SI201730964T patent/SI3484502T1/sl unknown
- 2017-04-27 ES ES17841780T patent/ES2899147T3/es active Active
- 2017-04-27 PT PT178417804T patent/PT3484502T/pt unknown
- 2017-04-27 RS RS20211337A patent/RS62558B1/sr unknown
- 2017-04-27 EP EP21192528.4A patent/EP3995140A1/en active Pending
- 2017-04-27 LT LTEPPCT/US2017/029953T patent/LT3484502T/lt unknown
- 2017-04-27 NZ NZ750885A patent/NZ750885A/en unknown
- 2017-04-27 SG SG11201901273TA patent/SG11201901273TA/en unknown
- 2017-04-27 CN CN201780057412.0A patent/CN109963582B/zh active Active
- 2017-04-27 DK DK17841780.4T patent/DK3484502T3/da active
- 2017-04-27 HR HRP20211628TT patent/HRP20211628T1/hr unknown
- 2017-04-27 CN CN202211658689.8A patent/CN115957309A/zh active Pending
- 2017-04-27 KR KR1020227025297A patent/KR20220107322A/ko not_active IP Right Cessation
- 2017-04-27 PL PL17841780T patent/PL3484502T3/pl unknown
- 2017-04-27 JP JP2019508828A patent/JP7316931B2/ja active Active
- 2017-04-27 IL IL264660A patent/IL264660B2/en unknown
- 2017-04-27 EP EP17841780.4A patent/EP3484502B1/en active Active
- 2017-04-27 MD MDE20190622T patent/MD3484502T2/ro unknown
- 2017-04-27 IL IL304946A patent/IL304946A/en unknown
- 2017-04-27 MA MA45692A patent/MA45692B1/fr unknown
- 2017-04-27 KR KR1020247007926A patent/KR20240036720A/ko active Search and Examination
- 2017-04-27 AU AU2017312722A patent/AU2017312722B2/en active Active
- 2017-04-27 KR KR1020197007543A patent/KR20190032614A/ko not_active IP Right Cessation
- 2017-04-27 HU HUE17841780A patent/HUE056294T2/hu unknown
- 2017-04-27 BR BR112019003172A patent/BR112019003172A2/pt not_active Application Discontinuation
- 2017-04-27 WO PCT/US2017/029953 patent/WO2018034712A1/en unknown
- 2017-04-27 MX MX2019001718A patent/MX2019001718A/es unknown
- 2017-04-27 CA CA3033051A patent/CA3033051A1/en active Pending
-
2019
- 2019-02-05 CL CL2019000304A patent/CL2019000304A1/es unknown
- 2019-06-28 US US16/456,717 patent/US20190321449A1/en not_active Abandoned
-
2020
- 2020-01-09 AU AU2020200181A patent/AU2020200181B2/en active Active
- 2020-07-16 ZA ZA2020/04834A patent/ZA202004834B/en unknown
-
2021
- 2021-09-28 AU AU2021240142A patent/AU2021240142A1/en active Pending
- 2021-11-05 CY CY20211100958T patent/CY1124695T1/el unknown
- 2021-12-15 JP JP2021203571A patent/JP7447069B2/ja active Active
-
2022
- 2022-01-24 US US17/582,974 patent/US20220152161A1/en active Pending
-
2023
- 2023-08-17 JP JP2023133021A patent/JP2023156459A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202004834B (en) | Blood plasma fractions as a treatment for aging-associated cognitive disorders | |
IL288712A (en) | Methods for treating abnormal movement disorders | |
HK1258518A1 (zh) | 用於眼病的基因療法 | |
SG11201608729RA (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders | |
HK1252996A1 (zh) | 用於治療癲癇的方法 | |
EP3119911A4 (en) | Methods for treating neurological disorders | |
IL267229A (en) | Methods of treating ocular disorders | |
HK1257272A1 (zh) | 治療hiv的工具 | |
GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
IL259381B (en) | Miravegron for the treatment of retinal diseases | |
PT3148588T (pt) | N,n-bis-2-mercaptoetilisoftalamida para o tratamento de doença de parkinson | |
ZA201707232B (en) | Treatment of a hydrocarbon component | |
GB201616286D0 (en) | Plasma abatement | |
GB201616285D0 (en) | Plasma abatement | |
GB201602784D0 (en) | New treatment of CFTR-related disorders |